



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: WALLACH=25

In re Application of:	)	Conf. No.: 7238
	)	
David WALLACH	)	Art Unit: 1636
	)	
Appln. No.: 09/671,687	)	Examiner: D. A. Lambertson
	)	
Filed: September 28, 2000	)	Washington, D.C.
	)	
For: NOVEL INHIBITOR OF NF-KB	)	March 28, 2005

**RESPONSE**

Honorable Commissioner for Patents  
U.S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window, **Mail Stop Amendment**  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, Virginia 22202

Sir:

This communication is responsive to the Office Action of October 1, 2004, petition and payment for a three month extension of time being attached hereto.

The Office Action and cited and applied references have been carefully reviewed. No claim is allowed. Claims 2, 3, 4, 20-24, 38-40, and 42-48 presently appear in this application and define patentable subject matter warranting their allowance. Reconsideration and allowance are hereby respectfully solicited.

Claims 2, 4, 20 and 38 have been rejected under 35 U.S.C. §102(b) as being anticipated by Nagase et al., *DNA Res.* 5:355-364 (December 1998). The examiner states that Nagase teaches the identification of KIAA0849, where the sequence of KIAA0849, at the time it was originally submitted, was 100% identical to amino acid residues